Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Background/Aims Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of this study was to identify clinical factors affect...

Full description

Bibliographic Details
Main Authors:	Chan-Young Ock, Shin-Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Format:	Article
Language:	English
Published:	The Korean Association of Internal Medicine 2019-09-01
Series:	The Korean Journal of Internal Medicine
Subjects:	crizotinib anaplastic lymphoma kinase lung neoplasms disease-free survival proportional hazards models
Online Access:	http://www.kjim.org/upload/pdf/kjim-2018-011.pdf

Similar Items

Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib
by: Carolina Valeria Mahuad, et al.
Published: (2016-06-01)

Treatment of Patients with ALK Gene Rearranged Non-small Cell Lung Cancer  after Resistance to Crizotinib
by: Tao JIANG, et al.
Published: (2015-02-01)

Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC
by: Emei GAO, et al.
Published: (2016-03-01)

A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report
by: Kashima J, et al.
Published: (2016-10-01)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
by: Moushumi Suryavanshi, et al.
Published: (2017-01-01)

Crizotinib in treatment of lung cancer
by: Arpita Singh, et al.
Published: (2017-01-01)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
by: Dennis Christoph Harrer, et al.
Published: (2020-10-01)

Bilateral breast adenocarcinomas with EML4—ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site?
by: Liu C, et al.
Published: (2016-06-01)

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
by: Daijiro Harada, et al.
Published: (2021-03-01)

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors
by: Amin, Amit Dipak, et al.
Published: (2016)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
by: Muhammad Wasi Alam, et al.
Published: (2019-07-01)

Renal Injury during Long-Term Crizotinib Therapy
by: Taro Yasuma, et al.
Published: (2018-09-01)

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study
by: Guangjian Yang, et al.
Published: (2019-10-01)

Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report
by: Henan BAI, et al.
Published: (2021-08-01)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
by: Qian Zhu, et al.
Published: (2017-06-01)

Anaplastic Lymphoma Kinase in Cutaneous Malignancies
by: Severine Cao, et al.
Published: (2017-09-01)

Crizotinib-Associated Renal Cysts: A Case Series
by: Garima Suman, et al.
Published: (2019-07-01)

Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
by: Yuka Kuriyama, et al.
Published: (2013-08-01)

A Case of Orbital Metastasis as Disease Progression of Anaplastic Lymphoma Kinase-Positive Lung Cancer Treated with Crizotinib
by: Yoshihiko Sakata, et al.
Published: (2015-01-01)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
by: Di Marino P, et al.
Published: (2020-03-01)

High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells
by: Domenico Sorrentino, et al.
Published: (2020-10-01)

Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
by: Tomonobu Koizumi, et al.
Published: (2016-04-01)

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report
by: Jun Osugi, et al.
Published: (2016-01-01)

Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
by: Ken Koshikawa, et al.
Published: (2020-06-01)

Anaplastic lymphoma kinase-positive pulmonary inflammatory myofibroblastic tumor with sarcomatous morphology and distant metastases: An unusual histomorphology and behavior
by: Bhawna Sethi, et al.
Published: (2015-01-01)

Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma
by: In Ho Choi, et al.
Published: (2015-07-01)

Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers
by: Abdulraheem Alshareef
Published: (2017-10-01)

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
by: Ja Yoon Heo, et al.
Published: (2019-11-01)

Molecular epidemiological study of microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene using immunohistochemistry as a cost effective alternative to fluorescence in situ hybridization for Indian patients with adenocarcinoma lung
by: Anurag Mehta, et al.
Published: (2017-01-01)

Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer
by: Mohieldin A, et al.
Published: (2018-11-01)

NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target
by: Elissa Andraos, et al.
Published: (2021-01-01)

Anaplastic large cell lymphoma ALK-negative clinically mimicking alcoholic hepatitis – a review
by: Fernando Peixoto Ferraz de Campos, et al.
Published: (2013-10-01)

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
by: Hyungjin Kim, et al.
Published: (2019-07-01)

ALK+ Anaplastic large cell lymphoma with extensive cardiac involvement: A rare case report and review of the literature
by: Kaniyappan Nambiyar, et al.
Published: (2021-01-01)

Clinical Significance of ROS1 Rearrangements in Non-small Cell Lung Cancer
by: Luting XU, et al.
Published: (2013-12-01)

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
by: Zilan Song, et al.
Published: (2015-01-01)

A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-rearranged Non-Small Cell Lung Cancer
by: Khashayar eEsfahani, et al.
Published: (2014-07-01)

Systemic ALK-positive anaplastic large cell lymphoma involving implant site: a fortuitous association
by: Mayur Parkhi, et al.
Published: (2021-08-01)

ALK Positive Anaplastic Large Cell Lymphoma Presenting as Extensive Bone Involvement
by: Smeeta Gajendra, et al.
Published: (2015-01-01)

Anaplastic lymphoma kinase negative anaplastic large cell lymphoma of hard palate as first clinical manifestation of acquired immune deficiency syndrome
by: Anjali Narwal, et al.
Published: (2016-01-01)